达英-35联合二甲双胍治疗多囊卵巢综合征临床观察

Clinical observation of Diane-35 combined with metformin in the treatment of polycystic ovary syndrome

目的观察达英-35联合二甲双胍治疗多囊卵巢综合征的临床疗效.方法选取2017年6月~2018年6月于我院就诊的多囊卵巢综合征80例患者,随机分为观察组和对照组,每组各40例,对照组应用达英-35治疗,观察组同时联合二甲双胍治疗,治疗后对两组患者的临床疗效及胰岛素抵抗、性激素水平进行检测.结果观察组患者治疗后的总有效率为95.00%,显著高于对照组的72.50%,差异有统计学意义(P<0.05).治疗前两组患者的LH、FSH、E2、T水平比较,差异无统计学意义(P>0.05);治疗后两组患者的LH、E2、T水平分别较治疗前明显降低,且观察组患者治疗后的上述各项指标显著低于对照组,组间比较差异具有显著性(P<0.05),观察组FSH水平治疗后分别较治疗前及对照组明显升高.治疗前两组患者的FINS、FPG水平及HOMA-IR比较,差异无统计学意义(P>0.05);治疗后两组患者的FINS、FPG、HOMA-IR分别较治疗前明显降低,且观察组患者治疗后的FINS、FPG、HOMA-IR显著低于对照组,组间比较差异具有显著性(P<0.05).结论达英-35、二甲双胍两种药物联合应用治疗多囊卵巢综合征疗效确切,且能明显改善患者的性激素水平及胰岛素抵抗,值得临床推广和应用.

Objective To observe the clinical efficacy of Diane-35 combined with metformin in the treatment of polycystic ovary syndrome. Methods 80 patients with polycystic ovary syndrome who were admitted to our hospital from June 2017 to June 2018 were selected and randomly divided into observation group and control group, with 40 cases in each group. The control group was given Diane-35 for treatment. The observation group was given metformin at the same time. After treatment, the clinical efficacy, insulin resistance and sex hormone levels of the two groups were tested. Results The total effective rate in the observation group was 95.00% after treatment, which was significantly higher than that of 72.50% in the control group, and the difference was statistically significant(P<0.05). There were no statistically significant differences in the levels of LH, FSH, E2 and T between the two groups before treatment(P>0.05);after treatment, the levels of LH, E2 and T in the two groups were significantly lower than those before treatment, and the above indicators after treatment in the observation group were significantly lower than those in the control group. The differences between the groups were statistically significant(P<0.05). The FSH level in the observation group after treatment was increased compared with before treatment and control group;there were no statistically significant differences in FINS, FPG levels and HOMA-IR between the two groups before treatment(P>0.05);after treatment, the levels of FINS and FPG, HOMA-IR in the two groups were significantly lower than those before treatment, the levels of FINS and FPG, HOMA-IR in the observation group were significantly lower than those in the control group. The differences between the groups were significant(P<0.05). Conclusion The combined application of Diane-35 and metformin is effective in the treatment of polycystic ovary syndrome, and can significantly improve the patient's sex hormone levels and insulin resistance, which is worthy of clinical promotion and application.